Home » EU to Rule on Safety of Novartis’s Gilenya MS Pill
EU to Rule on Safety of Novartis’s Gilenya MS Pill
Europe’s drug regulator will likely allow Novartis’ Gilenya to stay on the market without asking for much stricter safety warnings as it concludes a review of the multiple sclerosis pill initiated after reports of heart problems and the death of a patient who took the drug.
MarketWatch
MarketWatch
Upcoming Events
-
07May
-
14May
-
30May